fig2

Emerging resistance <i>vs.</i> losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena

Figure 2. Types of resistance. ICI: Immune checkpoint inhibitor; IRAE: immune-related adverse events; RCC: renal cell carcinoma. (Figure credits: Roy AM).

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/